ER+ breast cancer is highly reliant on an intact cyclin D-CDK4/6-Rb axis, as estrogen drives cyclin D1 expression leading to the formation of the cyclin D-CDK4/6 complex, ultimately inducing cell proliferation through the CDK4/6 pathway[36]. Here, CDK4 is linked to breast carcinoma.